The Scleroderma Association of NSW Inc.
cannot offer direct advice on treatment or available therapies.
It is up to each patient to make all relevant health decisions
In consultation with their own doctor or health professional.
|
• |
Early Endothelin Antagonist trial in mildly symptomatic Pulmonary Hypertension patients.
Needed: Volunteers for further trials
Early Endothelin Antagonist trial in mildly symptomatic Pulmonary Hypertension patients.
Aim: To demonstrate efficacy of Bosentan in patients with mildly symptomatic pulmonary hypertension
Background:
Pulmonary Hypertension is a condition effecting the blood vessels of the lungs which results in symptoms of breathlessness, fatigue, dizziness & chest pain on exertion.
About 15% of patients with scleroderma may have Pulmonary Hypertension
Previous studies have shown that bosentan therapy is effective in moderate to severe Pulmonary Hypertension
No currently approved treatment in patients with mild symptoms
Early detection and treatment of PAH may delay disease progression
The EARLY study is to determine if treatment with bosentan is effective if given to patients with mild symptoms
Primary Investigator: Associate professor Anne Keogh
Co-investigators: A/Prof. Peter Macdonald, Dr Chris Hayward, Dr Eugene Kotlyar
For questions regarding pulmonary hypertension program or the study please contact:
Annette Pidoux, RN (02) 8382-3785
Karen Brown, RN (02) 8382-3723
Carolyn Corrigan, RN (02) 8382-3265
Research
Focus: Please go here for
the complete article:
http://www.victorchang.com.au/research/ProfAnneKeogh.cfm?cid=80 Professor
Anne Keogh
Co-Investigators:
Volunteers for further trials are needed.
Randomised
trials underway, of drugs to treat pulmonary arterial hypertension associated
with scleroderma. (2) A novel agent in two
doses or placebo for 6 month period, for patients with pulmonary arterial
hypertension and scleroderma. Because of the placebo arm in this particular
trial, enrollments will be limited to those already on sildenafil or iloprost.
Anne Keogh
P: 61 2
8382 2641
•
Updated Updated
Tuesday, 08. April 2008
Professor Anne Keogh, MBBS MD FRACP
Joint Head, Transplant Program
Professor of Medicine, University of New South Wales
Telephone: +61-2-8382 2641
Fax: +61-2-8382 3084
Email:
amkeogh@stvincents.com.au
Eugene Kotlyar, MD
Karen Brown, RN
Carolyn Corrigan, RN
Annette Pidoux, RN
Carmen Herrera, RN
Collaborators:
Fatemah Aghlaghi; Rhode Island NY
John Ray; Clinical Pharmacology, St Vincent's Hospital
(1) Adding sildenafil or placebo, on top of bosentan for 3 month period. After
this the patient is entitled to free sildenafil for 12 months or more.
Professor in Medicine
Senior Heart Transplant Cardiologist
Joint Head Clinical Research Victor Chang Research Institute
St Vincent's Hospital
F: 61 2 8382 3084
Email: amkeogh@stvincents.com.au
The Scleroderma Association of NSW Inc.
cannot offer direct advice on treatment or available therapies.
It is up to each patient to make all relevant health decisions
In consultation with their own doctor or health professional.
"Laughter
is the shortest distance between two people." Victor Borge
If there are any broken links
please contact the
web
administrator